The U.S. FDA has just granted Breakthrough Therapy designation to a promising new treatment called del-zota (delpacibart zotadirsen) for people with Duchenne muscular dystrophy amenable to exon 44 skipping.
This is a major step forward. It means the drug has shown early signs of real benefit and will now be fast-tracked for approval in the U.S. The company behind it, Avidity Biosciences, plans to submit for full approval by the end of the year.
So what does this mean for Australians?
• New hope for families impacted by DMD exon 44. A targeted therapy that could slow disease progression and improve quality of life.
• Faster global momentum. FDA approval often leads to earlier access in other countries, including Australia.
• Potential clinical trials and early access programs here at home.
• Advocacy matters. This breakthrough strengthens the case for urgent access through the TGA and PBS.
• But we need to push for equity. Once available, we’ll need to ensure all eligible Australians can access it, regardless of postcode or income.
It’s a powerful reminder of how far research has come, and how important it is to keep pushing forward.
We’ll keep you updated as this progresses. Let’s keep the pressure on to make sure Australians aren’t left behind.
#Duchenne #DelZota #MuscularDystrophy #HopeForDMD #MDT
